Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

Detailed price information for Denali Therapeutics Inc (DNLI-Q) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN

Denali Therapeutics unveils portfolio goals for 2026, stock up

Denali Therapeutics Inc. DNLI recently outlined its roadmap for 2026 across its portfolio of investigational therapies for ...

The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review

Denali Therapeutics announced that results from its open-label Phase 1/2 trial of tividenofusp alfa for Hunter syndrome were published in the January 1, 2026 issue of The New England Journal of ...

Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review

Denali Therapeutics (DNLI) drew fresh interest after publishing Phase 1/2 trial results for its Hunter syndrome therapy, ...
TipRanks on MSN

Denali Therapeutics announces key milestones, priorities for 2026

Denali Therapeutics (DNLI) announced key anticipated milestones and priorities for 2026 across its portfolio of investigational therapies for ...

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...